{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:58:59Z","timestamp":1784285939120,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In clinical trials, eligibility criteria define a population who may benefit from the intervention without incurring undue safety risks. Despite their value, overly stringent eligibility criteria may pose barriers to inclusive recruitment. They may disproportionately exclude groups of people more likely to be diagnosed at later cancer stages, or have specific co-morbidities which can be associated with socio-demographic or ethnic background. The National Institute for Health and Care Research Innovations in Clinical Trial Design and Delivery for the Under-served (NIHR-INCLUDE) guidance highlighted several groups of people who may be underserved by clinical research. The aim of this review was to assess eligibility criteria in bladder and head and neck oncology trials and consider their potential impact on potentially underserved groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This scoping review included multi-centre, interventional, phase II and III trials in bladder or head and neck cancer, which recruited UK participants between 2013 and 2023. Trials were identified via searches of ClinicalTrials.gov, the International Standard Randomised Controlled Trial Number (ISRCTN) registry, and NIHR Clinical Portfolio Management System (CPMS). Trials\u2019 eligibility criteria were categorised and analysed narratively. Trial parameters (recruitment period, funding type, and whether they were of investigational medicinal products (IMPs)) were cross-tabulated with common exclusion criteria using Fisher\u2019s exact test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-eight bladder and 30 head and neck cancer trials met the selection criteria. Twenty-eight out of 68 (41%) had non-commercial sponsors. Fifty-six out of 68 (82%) were of IMPs. Forty-one out of 68 (60%) were industry-funded. Fifty-one out of 68 (75%) were for locally advanced, metastatic, or recurrent disease. Common exclusion criteria relating to pregnancy, performance status, HIV status, and cognitive ability may disproportionately impact some underserved groups suggested by the NIHR-INCLUDE guidance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review highlights common exclusion criteria which may disproportionately exclude underserved groups from UK bladder and head and neck oncology trials. To facilitate accessibility to oncology trials, sponsors and triallists should consider how potentially underrepresented groups may be safely included during development of eligibility criteria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09424-w","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:33:59Z","timestamp":1767850439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reviewing inclusivity of the UK bladder and head and neck oncology trial portfolio through eligibility criteria: a scoping review"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-6604","authenticated-orcid":false,"given":"Georgiana","family":"Synesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Kilburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Ching","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Gribble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgaine","family":"Stiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"9424_CR1","unstructured":"National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Committee on Women in Science, Engineering, and Medicine; Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research; Bibbins-Domingo K, Helman A, editors. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Washington (DC): National Academies Press (US). Appendix C, Improving Representativeness in Clinical Trials and Research: Facilitators to Recruitment and Retention of Underrepresented Groups. 2022. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK584402\/."},{"issue":"33","key":"9424_CR2","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","volume":"35","author":"ES Kim","year":"2017","unstructured":"Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. J Clin Oncol. 2017;35(33):3737\u201344.","journal-title":"J Clin Oncol"},{"issue":"33","key":"9424_CR3","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","volume":"35","author":"S Jin","year":"2017","unstructured":"Jin S, Pazdur R, Sridhara R. Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015. J Clin Oncol. 2017;35(33):3745\u201352.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9424_CR4","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.1996.14.4.1364","volume":"14","author":"SL George","year":"1996","unstructured":"George SL. Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol. 1996;14(4):1364\u201370.","journal-title":"J Clin Oncol"},{"issue":"9","key":"9424_CR5","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clon.2019.05.003","volume":"31","author":"S Karim","year":"2019","unstructured":"Karim S, Xu Y, Kong S, Abdel-Rahman O, Quan ML, Cheung WY. Generalisability of common oncology clinical trial eligibility criteria in the real world. Clin Oncol. 2019;31(9):e160\u20136.","journal-title":"Clin Oncol"},{"issue":"16","key":"9424_CR6","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1056\/NEJMp1615879","volume":"376","author":"JA Beaver","year":"2017","unstructured":"Beaver JA, Ison G, Pazdur R. Reevaluating eligibility criteria \u2014 balancing patient protection and participation in oncology trials. N Engl J Med. 2017;376(16):1504\u20135.","journal-title":"N Engl J Med"},{"key":"9424_CR7","unstructured":"NIHR. Improving inclusion of under-served groups in clinical research: guidance from INCLUDE project 2020 [Available from: https:\/\/www.nihr.ac.uk\/documents\/improving-inclusion-of-under-served-groups-in-clinical-research-guidance-from-include-project\/25435."},{"issue":"3","key":"9424_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/annonc\/mds526","volume":"24","author":"G Lyratzopoulos","year":"2013","unstructured":"Lyratzopoulos G, Abel GA, Brown CH, Rous BA, Vernon SA, Roland M, et al. Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer. Ann Oncol. 2013;24(3):843\u201350.","journal-title":"Ann Oncol"},{"issue":"33","key":"9424_CR9","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2008.16.5456","volume":"26","author":"CM Booth","year":"2008","unstructured":"Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK. Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol. 2008;26(33):5458\u201364.","journal-title":"J Clin Oncol"},{"key":"9424_CR10","unstructured":"Randomised trials: Cancer Research UK; 2025 [Available from: https:\/\/www.cancerresearchuk.org\/about-cancer\/find-a-clinical-trial\/what-clinical-trials-are\/randomised-trials."},{"key":"9424_CR11","unstructured":"Bladder cancer incidence statistics: Cancer Research UK; [Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bladder-cancer\/incidence#heading-Zero."},{"key":"9424_CR12","unstructured":"Head and neck cancers incidence statistics: Cancer Research UK; [Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/head-and-neck-cancers\/incidence#heading-Zero."},{"issue":"12","key":"9424_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.14740\/jocmr3617w","volume":"10","author":"S Roy","year":"2018","unstructured":"Roy S, Vallepu S, Barrios C, Hunter K. Comparison of comorbid conditions between cancer survivors and age-matched patients without cancer. J Clin Med Res. 2018;10(12):911\u20139.","journal-title":"J Clin Med Res"},{"issue":"1","key":"9424_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/0194599818796163","volume":"160","author":"DF Eytan","year":"2019","unstructured":"Eytan DF, Blackford AL, Eisele DW, Fakhry C. Prevalence of comorbidities among older head and neck cancer survivors in the United States. Otolaryngol Head Neck Surg. 2019;160(1):85\u201392.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"8","key":"9424_CR15","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41416-018-0029-6","volume":"118","author":"KF Brown","year":"2018","unstructured":"Brown KF, Rumgay H, Dunlop C, Ryan M, Quartly F, Cox A, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 2018;118(8):1130\u201341.","journal-title":"Br J Cancer"},{"key":"9424_CR16","unstructured":"Get data out: NHS Digital; 2024 [Available from: https:\/\/digital.nhs.uk\/ndrs\/our-work\/ncras-work-programme\/get-data-out."},{"issue":"5","key":"9424_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","volume":"19","author":"M Lechner","year":"2022","unstructured":"Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19(5):306\u201327.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"9424_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12910-023-00987-w","volume":"24","author":"D Patel","year":"2023","unstructured":"Patel D, Kilburn L, Fox L, Hall E, Bliss J, Lewis R. Equality, diversity, and inclusion in oncology clinical trials: an audit of essential documents and data collection against INCLUDE under-served groups in a UK academic trial setting. BMC Med Ethics. 2023;24(1):105.","journal-title":"BMC Med Ethics"},{"issue":"7","key":"9424_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"key":"9424_CR20","unstructured":"Synesi G. Assessing the eligibility criteria of UK phase II and III randomised controlled bladder and head & neck oncology clinical trials: protocol for a scoping review 2023 [Available from: https:\/\/osf.io\/x3h78."},{"issue":"3","key":"9424_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.trecan.2020.11.010","volume":"7","author":"PE L\u00f8nning","year":"2021","unstructured":"L\u00f8nning PE. Assessing novel therapies based on late-stage efficacy: a dangerous concept? Trends Cancer. 2021;7(3):181\u20135.","journal-title":"Trends Cancer"},{"issue":"3","key":"9424_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/infdis\/jis698","volume":"207","author":"X Li","year":"2013","unstructured":"Li X, Gao L, Li H, Gao J, Yang Y, Zhou F, et al. Human papillomavirus infection and laryngeal cancer risk: a systematic review and meta-analysis. J Infect Dis. 2013;207(3):479\u201388.","journal-title":"J Infect Dis"},{"issue":"3","key":"9424_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41416-019-0602-7","volume":"122","author":"ME Sabatini","year":"2020","unstructured":"Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. Br J Cancer. 2020;122(3):306\u201314.","journal-title":"Br J Cancer"},{"issue":"5","key":"9424_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/lgbt.2016.0142","volume":"4","author":"B Brown","year":"2017","unstructured":"Brown B, Poteat T, Marg L, Galea JT. Human papillomavirus-related cancer surveillance, prevention, and screening among transgender men and women: neglected populations at high risk. LGBT Health. 2017;4(5):315\u20139.","journal-title":"LGBT Health"},{"key":"9424_CR25","unstructured":"Nash S, Desai S, Croxford S, Guerra L, Lowndes C, Connor N, Gill ON. Progress towards ending the HIV epidemic in the United Kingdom: 2018 report. Public Health England, London. 2018."},{"issue":"732","key":"9424_CR26","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2023.0023","volume":"73","author":"J Brown","year":"2023","unstructured":"Brown J, Pfeiffer RM, Shrewsbury D, O\u2019Callaghan S, Berner AM, Gadalla SM, et al. Prevalence of cancer risk factors among transgender and gender diverse individuals: a cross-sectional analysis using UK primary care data. Br J Gen Pract. 2023;73(732):e486.","journal-title":"Br J Gen Pract"},{"issue":"2","key":"9424_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0958-3947(99)00010-2","volume":"24","author":"MB Podgorsak","year":"1999","unstructured":"Podgorsak MB, Meiler RJ, Kowal H, Kishel SP, Orner JB. Technical management of a pregnant patient undergoing radiation therapy to the head and neck. Med Dosim. 1999;24(2):121\u20138.","journal-title":"Med Dosim"},{"issue":"4","key":"9424_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1015-9584(08)60086-X","volume":"31","author":"VL Yu Chow","year":"2008","unstructured":"Yu Chow VL, Wai Chan JY, Man Ng RW, Wei WI. Management of head and neck tumours during pregnancy: case report and literature review. Asian J Surg. 2008;31(4):199\u2013203.","journal-title":"Asian J Surg"},{"issue":"4","key":"9424_CR29","doi-asserted-by":"publisher","first-page":"e245625","DOI":"10.1001\/jamanetworkopen.2024.5625","volume":"7","author":"P Gougis","year":"2024","unstructured":"Gougis P, Hamy A-S, Jochum F, Bihan K, Carbonnel M, Salem J-E, et al. Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns. JAMA Netw Open. 2024;7(4):e245625-e.","journal-title":"JAMA Netw Open"},{"key":"9424_CR30","unstructured":"Raleigh V, Holmes J. The health of people from ethnic minority groups in England: The Kings Fund; 2021 [Available from: https:\/\/www.kingsfund.org.uk\/publications\/health-people-ethnic-minority-groups-england."},{"issue":"2","key":"9424_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","volume":"2","author":"A Vogt","year":"2017","unstructured":"Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017;2(2):e000172.","journal-title":"ESMO Open"},{"key":"9424_CR32","unstructured":"Adult smoking habits in the UK: 2021: The Office for National Statistics; 2022 [Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/healthandlifeexpectancies\/bulletins\/adultsmokinghabitsingreatbritain\/2021."},{"issue":"4","key":"9424_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/nop\/npaa008","volume":"7","author":"K Mulhauser","year":"2020","unstructured":"Mulhauser K, Marotta DA, Gerstenecker A, Wilhelm G, Myers T, Gammon M, et al. Capacity to consent to research participation in adults with metastatic cancer: comparisons of brain metastasis, non-CNS metastasis, and healthy controls. Neuro-Oncol Pract. 2020;7(4):439\u201345.","journal-title":"Neuro-Oncol Pract"},{"issue":"1","key":"9424_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04406-y","volume":"21","author":"V Shepherd","year":"2020","unstructured":"Shepherd V. An under-represented and underserved population in trials: methodological, structural, and systemic barriers to the inclusion of adults lacking capacity to consent. Trials. 2020;21(1):445.","journal-title":"Trials"},{"issue":"1","key":"9424_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-07944-x","volume":"25","author":"V Shepherd","year":"2024","unstructured":"Shepherd V, Joyce K, Lewis A, Flynn S, Clout M, Nocivelli B, et al. Improving the inclusion of an under-served group in trials: development and implementation of the INCLUDE impaired capacity to consent framework. Trials. 2024;25(1):83.","journal-title":"Trials"},{"issue":"3","key":"9424_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jgo.2019.11.001","volume":"11","author":"EB Ludmir","year":"2020","unstructured":"Ludmir EB, Subbiah IM, Mainwaring W, Miller AB, Lin TA, Jethanandani A, et al. Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. Journal of geriatric oncology. 2020;11(3):451\u20134.","journal-title":"Journal of geriatric oncology"},{"key":"9424_CR37","doi-asserted-by":"crossref","unstructured":"Kingston A, Robinson L, Booth H, Knapp M, Jagger C, project ftM. Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model. Age and Ageing. 2018;47(3):374\u201380.","DOI":"10.1093\/ageing\/afx201"},{"issue":"1","key":"9424_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-16-1367","volume":"23","author":"MK Chuk","year":"2017","unstructured":"Chuk MK, Mulugeta Y, Roth-Cline M, Mehrotra N, Reaman GH. Enrolling adolescents in disease\/target-appropriate adult oncology clinical trials of investigational agents. Clin Cancer Res. 2017;23(1):9\u201312.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"9424_CR39","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.juro.2006.11.060","volume":"177","author":"AZ Weizer","year":"2007","unstructured":"Weizer AZ, Joshi D, Daignault S, Kinnaman M, Hussain M, Montie JE, et al. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol. 2007;177(4):1287\u201393.","journal-title":"J Urol"},{"issue":"25","key":"9424_CR40","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.2015.62.1854","volume":"33","author":"ES Kim","year":"2015","unstructured":"Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, et al. Modernizing eligibility criteria for molecularly driven trials. J Clin Oncol. 2015;33(25):2815\u201320.","journal-title":"J Clin Oncol"},{"key":"9424_CR41","unstructured":"HRA and MHRA draft inclusion and diversity guidance: Health Research Authority; 2024 [Available from: https:\/\/www.hra.nhs.uk\/about-us\/news-updates\/hra-mhra-guidance-developing-and-submitting-inclusion-and-diversity-plan\/."},{"key":"9424_CR42","unstructured":"Stiles M, Lidington E, Ching J, Deutsch A, Hall E, Maudsley J, et al., editors. DISTINCT: exploring public views on collecting data to monitor inclusivity of cancer clinical trials.\u00a0Edinburgh: International Clinical Trials Methodology Conference; 2024."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09424-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:08:14Z","timestamp":1768165694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09424-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9424"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09424-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}